Get the Stockscreener App
9.89
5.99%
-0.63
After Hours:
9.90
0.010
+0.10%
Monte Rosa Therapeutics Inc stock is traded at $9.89, with a volume of 2.70M.
It is down -5.99% in the last 24 hours and down -29.71% over the past month.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
See More
Previous Close:
$10.52
Open:
$10.45
24h Volume:
2.70M
Relative Volume:
1.44
Market Cap:
$843.75M
Revenue:
$42.95M
Net Income/Loss:
$-130.01M
P/E Ratio:
-6.0757
EPS:
-1.6278
Net Cash Flow:
$-19.66M
1W Performance:
+0.20%
1M Performance:
-29.71%
6M Performance:
-43.65%
1Y Performance:
-4.90%
1-Day Range:
$9.8525
$10.54
1-Week Range:
$9.68
$10.75
52-Week Range:
$8.9431
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
9.89 | 843.75M | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-26 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6%What's Next? - MarketBeat
Monte Rosa Therapeutics Announces Positive Phase 1 Results for MRT-8102 in GFORCE-1 Trial - Kalkine Media
Monte Rosa Therapeutics, Inc. (GLUE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - benzinga.com
Monte Rosa Therapeutics (Nasdaq:GLUE)Stock Analysis - Simply Wall Street
Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE - MarketBeat
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Share Price, GLUE Stock News, GLUE Share Price & Updates - Kalkine
Can Monte Rosa Therapeutics (NASDAQ:GLUE) Rewrite Its Story? - Kalkine Media
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone - Yahoo Finance
Opaleye Management Inc. Acquires Shares of 745,000 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com Canada
Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com India
Wellington Management Group LLP Buys 78,635 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Outperform" Rating from Wedbush - MarketBeat
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - moomoo.com
Monte Rosa Earns $50M Milestone Payment as Novartis Starts Phase 2 Trial - Minichart
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 - Investing News Network
Monte Rosa Announces $50M Milestone as Novartis Starts Phase 2 for MRT-6160 in Sjögren’s - TradingView
A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial - Stock Titan
How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial - webull.com
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet - Seeking Alpha
Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
GLUE stock gains on investor conference plans and Monte Rosa outlook - ad-hoc-news.de
Six new hires get stock awards from Monte Rosa - Stock Titan
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
BlackRock Inc. Purchases New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Is Monte Rosa Therapeutics (GLUE) Redefining Its Prostate Cancer Strategy With MRT-2359’s Phase 2 Combo Bet? - simplywall.st
615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC - MarketBeat
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Discipline and Rules-Based Execution in GLUE Response - Stock Traders Daily
ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive - Sahm
Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - marketscreener.com
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - Yahoo Finance
Monte (GLUE) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Current Update; Session Move - vinanet.vn
Monte (GLUE) Shares: Finishes 6.28% Lower at $14.78 in Latest Trading; Key Range: the $14.04 to $15.52 Range Remains in Focus for the Current SessionSentiment Divergence - vinanet.vn
Monte (GLUE) Market Snapshot: Moves 1.30% Lower to $15.18 for the Current Session - vinanet.vn
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Warmuth Markus | President & CEO |
Jul 16 '26 |
Sale |
23.18 |
9,500 |
220,219 |
585,038 |
| MARKUS WARMUTH | Officer |
Jul 16 '26 |
Proposed Sale |
23.18 |
9,500 |
220,219 |
0 |
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Option Exercise |
3.98 |
4,351 |
17,317 |
66,722 |
| Champoux Jennifer | Officer |
Jul 15 '26 |
Proposed Sale |
23.38 |
4,351 |
101,730 |
0 |
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Sale |
23.38 |
4,351 |
101,730 |
62,371 |
| Townson Sharon | Chief Scientific Officer |
Jul 06 '26 |
Sale |
23.31 |
6,000 |
139,849 |
67,845 |
| Townson Sharon | Chief Scientific Officer |
Jul 06 '26 |
Option Exercise |
6.14 |
6,000 |
36,840 |
73,845 |
| Janku Filip | Chief Medical Officer |
Jun 30 '26 |
Sale |
24.50 |
5,407 |
132,472 |
60,612 |
| FILIP JANKU | Officer |
Jun 30 '26 |
Proposed Sale |
23.90 |
5,407 |
129,227 |
0 |
| Janku Filip | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
13.41 |
5,407 |
72,508 |
66,019 |
7.08%
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):